Pneumagen Ltd.

https://www.pneumagen.com

LinkedIn: https://www.linkedin.com/company/pneumagen-limited

Pneumagen is a clinical- stage biotech company developing Neumifil, its lead product, as an intranasal drug for the prophylaxis and treatment of a broad range of viral respiratory tract infections (RTIs). Neumifil is a novel, engineered multivalent Carbohydrate Binding Molecule (mCBM), which is being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus infections including COVID-19. Neumifil acts by directly binding and preventing the entry of the viral pathogens into the lungs with reduced susceptibility to direct viral resistance. Neumifil was generated using Pneumagen’s proprietary GlycoTarge™ technology that acts by stopping viruses at the site of infection, reducing their ability both to enter cells and to migrate to the lungs. In addition to Neumifil, Pneumagen is harnessing its GlycoTarge™platform to enable the development of a pipeline of intranasal therapies targeting other infectious lung diseases. *

	Start	2016-04-01 established
	Industry	anti-infective drug
	Person	Thomson, Douglas (Pneumagen 201604– CEO + Founder)
	Person 2	Bamforth, Mark R. (Brammer Bio 201903 CEO + Co-Founder)

	Region	St. Andrews, Fife
	Country	United Kingdom (GB)
	Street	Doubledykes Road Kinburn Castle
	City	KY16 9DR St. Andrews, Fife
		Address record changed: 2021-09-18

Basic data	Employees	n. a.

		* Document for »About Section«: Pneumagen Ltd.. (1/19/22). "Press Release: Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)". St Andrew

		Record changed: 2023-07-10

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Pneumagen Ltd.

[1] Pneumagen Ltd.. (1/19/22). "Press Release: Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)". St Andrew...

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)